Valentina Băicuianu and Adrian Grecu of the APMGR, share their insights on the deteriorating environment for generics in Romania, with unfavourable pricing methodology and a rising and an unpredictable clawback tax. They reveal the solutions that the generics industry has proposed to authorities and outline their continued endeavours to convince the government to become a strategic partner in helping to amend the current situation
EU markets have an adoption rate of 50 to 90 per cent for biosimilars, and they are supported by EMA. Romania must follow suit if it wants to improve access and optimize its budget. Valentina Băicuianu
